RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 St
RDHL: RedHill Biopharma Ltd.
2020-07-31 07:00:10
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
2020-07-31 07:00:10
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.